Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Spigset

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|July 28, 2001
[The transfer of selective serotonin reuptake inhibitors to human milk]H Nordeng, Y K Bergsholm, E Bøhler, et al.
Nordisk Medicin|January 1, 1993
[Calcitonin as medication in pain?]O Spigset, T Mjörndal, E Vinge, et al.
Acta Psychiatrica Scandinavica|September 3, 2017
Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapineI Castberg, A A Westin, E Skogvoll, et al.
European Journal of Clinical Pharmacology|November 9, 2001
Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypesS Hägg, O Spigset, H A Lakso, et al.
Journal of Clinical Psychopharmacology|July 31, 2001
Myocarditis related to clozapine treatmentS Hägg, O Spigset, A Bate, et al.
British Journal of Clinical Pharmacology|March 28, 1998
Non-linear fluvoxamine dispositionO Spigset, K Granberg, S Hägg, et al.
European Journal of Clinical Pharmacology|August 24, 1999
Fluvoxamine is a potent inhibitor of tacrine metabolism in vivoJ T Larsen, L L Hansen, O Spigset, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphismsO Spigset, K Granberg, S Hägg, et al.
Biological Psychiatry|March 11, 1999
Platelet [3H]paroxetine and [3H]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapyK Smedh, O Spigset, P Allard, et al.
Therapeutic Drug Monitoring|June 1, 1994
Carbamazepine interference in a high-performance liquid chromatography analysis for perphenazineO Spigset, L Carleborg, T Mjörndal, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|July 28, 2001
[The transfer of selective serotonin reuptake inhibitors to human milk]H Nordeng, Y K Bergsholm, E Bøhler, et al.
Nordisk Medicin|January 1, 1993
[Calcitonin as medication in pain?]O Spigset, T Mjörndal, E Vinge, et al.
Acta Psychiatrica Scandinavica|September 3, 2017
Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapineI Castberg, A A Westin, E Skogvoll, et al.
European Journal of Clinical Pharmacology|November 9, 2001
Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypesS Hägg, O Spigset, H A Lakso, et al.
Journal of Clinical Psychopharmacology|July 31, 2001
Myocarditis related to clozapine treatmentS Hägg, O Spigset, A Bate, et al.
British Journal of Clinical Pharmacology|March 28, 1998
Non-linear fluvoxamine dispositionO Spigset, K Granberg, S Hägg, et al.
European Journal of Clinical Pharmacology|August 24, 1999
Fluvoxamine is a potent inhibitor of tacrine metabolism in vivoJ T Larsen, L L Hansen, O Spigset, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphismsO Spigset, K Granberg, S Hägg, et al.
Biological Psychiatry|March 11, 1999
Platelet [3H]paroxetine and [3H]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapyK Smedh, O Spigset, P Allard, et al.
Therapeutic Drug Monitoring|June 1, 1994
Carbamazepine interference in a high-performance liquid chromatography analysis for perphenazineO Spigset, L Carleborg, T Mjörndal, et al.
Pageof 13